These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15234863)
1. Creation of a drug fund for post-clinical trial access to antiretrovirals. Ananworanich J; Cheunyam T; Teeratakulpisarn S; Boyd MA; Ruxrungtham K; Lange J; Cooper D; Phanuphak P Lancet; 2004 Jul 3-9; 364(9428):101-2. PubMed ID: 15234863 [No Abstract] [Full Text] [Related]
2. Standards of care in the antiretroviral rollout world. Singh JA Lancet; 2004 Sep 11-17; 364(9438):920-2. PubMed ID: 15364176 [No Abstract] [Full Text] [Related]
3. The obligation to provide antiretroviral treatment in HIV prevention trials. Lo B; Padian N; Barnes M AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698 [TBL] [Abstract][Full Text] [Related]
4. Reciprocity and post-trial access for participants in antiretroviral therapy trials. Merritt M; Grady C AIDS; 2006 Sep; 20(14):1791-4. PubMed ID: 16954719 [No Abstract] [Full Text] [Related]
5. Financial barrier to HIV treatment. Aust Nurs Midwifery J; 2014 Mar; 21(8):7. PubMed ID: 24724191 [No Abstract] [Full Text] [Related]
6. Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention. Gayle H; Lange JM Lancet; 2004 Jul 3-9; 364(9428):6-8. PubMed ID: 15234835 [No Abstract] [Full Text] [Related]
7. Learning and doing: operational research and access to HIV treatment in Africa. Katzenstein D; Koulla-Shiro S; Laga M; Moatti JP AIDS; 2010 Jan; 24 Suppl 1():S1-4. PubMed ID: 20023435 [No Abstract] [Full Text] [Related]
8. Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials. Haire B; Jordens C Dev World Bioeth; 2015 Aug; 15(2):85-97. PubMed ID: 26193849 [TBL] [Abstract][Full Text] [Related]
9. HIV groups call on US government to fund preventive drug treatment. Roehr B BMJ; 2011 Aug; 343():d5412. PubMed ID: 21865272 [No Abstract] [Full Text] [Related]
10. Post-trial access to antiretrovirals: who owes what to whom? Millum J Bioethics; 2011 Mar; 25(3):145-54. PubMed ID: 19594728 [TBL] [Abstract][Full Text] [Related]
11. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina. Sengupta S N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558 [TBL] [Abstract][Full Text] [Related]
12. Helsinki Declaration revisions. Schuklenk U Issues Med Ethics; 2001; 9(1):29. PubMed ID: 16334459 [No Abstract] [Full Text] [Related]
13. Prioritizing antiretrovirals for second-line therapy in resource-limited countries. Naidoo K AIDS Clin Care; 2008 May; 20(5):43. PubMed ID: 19230296 [No Abstract] [Full Text] [Related]
14. Antiretroviral therapy in resource-poor settings: scaling up inequalities? Egger M; Boulle A; Schechter M; Miotti P Int J Epidemiol; 2005 Jun; 34(3):509-12. PubMed ID: 15941732 [No Abstract] [Full Text] [Related]
15. Brazil celebrates 10 years of universal access to antiretrovirals. Morales K BMJ; 2006 Nov; 333(7576):989. PubMed ID: 17095776 [No Abstract] [Full Text] [Related]
17. The marriage of science and optimized HIV care in resource-limited settings. Calmy A; Pizzocolo C; Pizarro L; Brücker G; Murphy R; Katlama C; AIDS; 2008 Nov; 22(17):2227-30. PubMed ID: 18981761 [No Abstract] [Full Text] [Related]
18. COMMENTARY: understanding the benefits of pediatric anti-retroviral treatment in resource-limited settings. Hetherington S Pediatr Infect Dis J; 2009 Jan; 28(1):41-2. PubMed ID: 19057455 [TBL] [Abstract][Full Text] [Related]
19. Calculating the affordability of antiretrovirals in St Lucia. Reddock JR; Grignon M West Indian Med J; 2013; 62(4):350-6. PubMed ID: 24756598 [TBL] [Abstract][Full Text] [Related]
20. One standard, not two. Lancet; 2003 Sep; 362(9389):1005. PubMed ID: 14522524 [No Abstract] [Full Text] [Related] [Next] [New Search]